erlotinib

You have access
Erlotinib Induces Cell Death by Blocking NIX-mediated Mitophagy Through Lysosomal Swelling in IDH1-mutant Cholangiocarcinoma
YONGHYUN KANG, CHORONG KIM, CHAN YEOP JEONG, DA SOL LEE, CHANGHOON YOO, INKEUN PARK, SEONMIN LEE and KYU-PYO KIM

Anticancer Research March 2026, 46 (3) 1349-1364; DOI: https://doi.org/10.21873/anticanres.18034
Open Access
Anti-tumor Effects of Erlotinib via Thymidylate Synthase Down-regulation in Pancreatic Cancer Cells
SATOSHI TABUCHI, TETSURO TOMINAGA, TOMOSHI TSUCHIYA, RYOICHIRO DOI, JYUNICHI ARAI, TAKASHI NONAKA, TAKURO MIYAZAKI, TATSUO INAMINE, KAZUHIRO TSUKAMOTO and KEITARO MATSUMOTO

Anticancer Research February 2025, 45 (2) 503-510; DOI: https://doi.org/10.21873/anticanres.17439
You have access
EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
GIUSEPPINA IMPROTA, GIULIA VITA, ALFREDO TARTARONE, GIOVANNI CALICE, LUDMILA CARMEN OMER and ANGELA ZUPA

Anticancer Research January 2025, 45 (1) 335-340; DOI: https://doi.org/10.21873/anticanres.17421
You have access
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study
SUNG HEE LIM, JUNG YONG HONG, JOON OH PARK, YOUNG SUK PARK and SEUNG TAE KIM

Anticancer Research September 2023, 43 (9) 4161-4167; DOI: https://doi.org/10.21873/anticanres.16607
You have access
Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression
LENA HUBER, RICHARD BIRK, MANUEL KNUETTEL, NICOLE ROTTER, CHRISTOPH ADERHOLD, CLAUDIA SCHERL, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research July 2022, 42 (7) 3403-3411; DOI: https://doi.org/10.21873/anticanres.15827
You have access
Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems
HYUN-KYUNG LEE, MIN HYE NOH, SEUNG-WOO HONG, SEUNG-MI KIM, SUNG HYUN KIM, YEONG SEOK KIM, V. COURTNEY BROADDUS and DAE YOUNG HUR

Anticancer Research March 2021, 41 (3) 1261-1269; DOI: https://doi.org/10.21873/anticanres.14883
You have access
Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC
RICHARD BIRK, ANGELA SCHELL, CHRISTOPH ADERHOLD, STEPHAN HOCH, LENA HUBER, CORNELIA EMIKA MUELLER, ANNE LAMMERT, CLAUDIA SCHERL, NICOLE ROTTER, J. ULRICH SOMMER and BENEDIKT KRAMER

Anticancer Research November 2020, 40 (11) 6195-6203; DOI: https://doi.org/10.21873/anticanres.14639
You have access
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma
BENDIKT KRAMER, ANGELA SCHELL, CHRISTOPH ADERHOLD, LENA HUBER, C. EMIKA MUELLER, NICOLE ROTTER and RICHARD BIRK

Anticancer Research July 2020, 40 (7) 3847-3855; DOI: https://doi.org/10.21873/anticanres.14374
You have access
Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group
GIANNIS MOUNTZIOS, XANTHIPPI MAVROPOULOU, GEORGIA-ANGELIKI KOLIOU, HELENA LINARDOU, EPAMINONTAS SAMANTAS, PARIS KOSMIDIS, GEORGE FOUNTZILAS, APHRODITE CHARITANDI and ANNA KALOGERA-FOUNTZILA

Anticancer Research April 2020, 40 (4) 2095-2106; DOI: https://doi.org/10.21873/anticanres.14168
You have access
Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status
LENA HUBER, RICHARD BIRK, NICOLE ROTTER, CHRISTOPH ADERHOLD, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research February 2020, 40 (2) 825-835; DOI: https://doi.org/10.21873/anticanres.14014

Main menu

User menu

Search

erlotinib

Pages